Nicanor Obaldía, Joao Luiz Da Silva Filho, Marlon Núñez, Katherine A Glass, Tate Oulton, Fiona Achcar, Grennady Wirjanata, Manoj Duraisingh, Philip Felgner, Kevin Ka Tetteh, Zbynek Bozdech, Thomas D Otto, Matthias Marti
{"title":"Sterile protection against <i>P. vivax</i> malaria by repeated blood stage infection in the <i>Aotus</i> monkey model.","authors":"Nicanor Obaldía, Joao Luiz Da Silva Filho, Marlon Núñez, Katherine A Glass, Tate Oulton, Fiona Achcar, Grennady Wirjanata, Manoj Duraisingh, Philip Felgner, Kevin Ka Tetteh, Zbynek Bozdech, Thomas D Otto, Matthias Marti","doi":"10.26508/lsa.202302524","DOIUrl":null,"url":null,"abstract":"<p><p>The malaria parasite <i>Plasmodium vivax</i> remains a major global public health challenge, and no vaccine is approved for use in humans. Here, we assessed whether <i>P. vivax</i> strain-transcendent immunity can be achieved by repeated infection in <i>Aotus</i> monkeys. Sterile immunity was achieved after two homologous infections, whereas subsequent heterologous challenge provided only partial protection. IgG levels based on <i>P. vivax</i> lysate ELISA and protein microarray increased with repeated infections and correlated with the level of homologous protection. Parasite transcriptional profiles provided no evidence of major antigenic switching upon homologous or heterologous challenge. However, we observed significant sequence diversity and transcriptional differences in the <i>P. vivax</i> core gene repertoire between the two strains used in the study, suggesting that partial protection upon heterologous challenge is due to molecular differences between strains rather than immune evasion by antigenic switching. Our study demonstrates that sterile immunity against <i>P. vivax</i> can be achieved by repeated homologous blood stage infection in <i>Aotus</i> monkeys, thus providing a benchmark to test the efficacy of candidate blood stage <i>P. vivax</i> malaria vaccines.</p>","PeriodicalId":18081,"journal":{"name":"Life Science Alliance","volume":"7 3","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10756917/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life Science Alliance","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.26508/lsa.202302524","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/1 0:00:00","PubModel":"Print","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The malaria parasite Plasmodium vivax remains a major global public health challenge, and no vaccine is approved for use in humans. Here, we assessed whether P. vivax strain-transcendent immunity can be achieved by repeated infection in Aotus monkeys. Sterile immunity was achieved after two homologous infections, whereas subsequent heterologous challenge provided only partial protection. IgG levels based on P. vivax lysate ELISA and protein microarray increased with repeated infections and correlated with the level of homologous protection. Parasite transcriptional profiles provided no evidence of major antigenic switching upon homologous or heterologous challenge. However, we observed significant sequence diversity and transcriptional differences in the P. vivax core gene repertoire between the two strains used in the study, suggesting that partial protection upon heterologous challenge is due to molecular differences between strains rather than immune evasion by antigenic switching. Our study demonstrates that sterile immunity against P. vivax can be achieved by repeated homologous blood stage infection in Aotus monkeys, thus providing a benchmark to test the efficacy of candidate blood stage P. vivax malaria vaccines.
间日疟原虫仍然是全球公共卫生面临的一大挑战,目前还没有疫苗被批准用于人类。在这里,我们评估了在奥特斯猴中重复感染间日疟原虫菌株是否能获得超越性免疫。两次同源感染后可获得无菌免疫,而随后的异源挑战只能提供部分保护。根据间日疟原虫裂解物酶联免疫吸附试验和蛋白质芯片检测,IgG水平随着重复感染而增加,并与同源保护水平相关。寄生虫转录图谱没有提供同源或异源挑战时主要抗原转换的证据。然而,我们观察到研究中使用的两种毒株之间的 P. vivax 核心基因库存在明显的序列多样性和转录差异,这表明异源挑战时的部分保护是由于毒株之间的分子差异,而不是抗原转换导致的免疫逃避。我们的研究表明,通过在奥特斯猴中反复进行同源血期感染,可以获得针对间日疟的无菌免疫,从而为测试候选血期间日疟疫苗的效力提供了一个基准。
期刊介绍:
Life Science Alliance is a global, open-access, editorially independent, and peer-reviewed journal launched by an alliance of EMBO Press, Rockefeller University Press, and Cold Spring Harbor Laboratory Press. Life Science Alliance is committed to rapid, fair, and transparent publication of valuable research from across all areas in the life sciences.